Effect of HIV type 1 Tat protein on butyric acid-induced differentiation in a hematopoietic progenitor cell line

AIDS Research and Human Retroviruses

Volumn 12, Issue 16, 1996, Pages 1529-1536

  Mondal, Debasis ^a   Agrawal, Krishna C ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; TRANSACTIVATOR PROTEIN;

ARTICLE; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VIRUS CELL INTERACTION;

EID: 0029864486     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.1529     Document Type: Article

References (47)

1. Bagnara GP, Zauli G, Giovannini M, Re MC, Furlini G, and La Placa M: Early loss of circulating hemopoietic progenitors in HIV-1 infected subjects. Exp Hematol 1990;18:426-430.
2. Scadden DT, Zon Li, and Groopman JE: Pathophysiology and management of HIV associated hematologic disorders. Blood 1989;74:1455-1463.
3. Li Zon, Arkin C, and Groopman JE: Hematologic manifestations of the human immunodeficiency virus (HIV). Br J Haematol 1987;66:251-256.
4. Carlo Stella C, Gauser A, and Hoelzer D: Defective in vitro growth of the hemopoietic progenitor cells in AIDS. J Clin Invest 1987;80:286-293.
5. Folks TM: Human immunodeficiency virus in bone marrow: Still more questions than answers. Blood 1991;77:1625-1626.
6. Folks TM, Kessler SW, Orenstein JM, Justment JS, Laffe E, and Fauci AS: Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988;242 :919-922.
7. Steinberg HN, Crumpacker CS, and Chatis PA: In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. J Virol 1991;65:1765-1769.
8. Davis BR, Marx JC, Johnson CE, et al.: Absent or rare HIV infection of bone marrow stem progenitor cells in vivo. J Virol 1991;65:1985-1990.
9. Lotem J and Sachs L: Selective regulation of the activity of different hematopoietic regulatory proteins by transforming growth factor β1 in normal and leukemic myeloid cells. Blood 1990;76;1315-1322.
10. +) cells in AIDS patients. J Infect Dis 1992;166:710-706.
11. Zauli G, Davis BR, Re MC, Visani G, Furlini G, and La Placa M: Tat protein stimulates production of transforming growth factor-β1 by marrow macrophages: A potential mechanism for HIV-1 induced hematopoietic suppression. Blood 1992;80:3036-3043.
12. +) hematopoietic progenitor cells. Arch Virol 1992;14:878-886.
13. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC, and Wong-Staal F: The trans-activator gene of HTLV-III is essential for virus replication. Nature (London) 1986;320:367-371.
14. Dingwall C, Emberg I, Gait MJ, et al.: Human immunodeficiency virus 1 Tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci USA 1989;86:6525-6929.
15. Rosen CA, Sodroski JC, and Haseltine WA: The location of cis-acting regulatory sequences in the human T-cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 1985;41: 813-823.
16. Sodroski J, Rosen C, Wong-Staal F, Salahuddin SZ, Popovic M, Arya S, Gallo RC, and Haseltine WA: Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science 1985;227:171-173.
17. Rosen CA, Sodroski JG, Goh WC, Dayton AI, Lippke J, and Haseltine WA: Post-transcriptional regulation accounts for the trans-activation of human T-lymphotropic virus type-III. Nature (London) 1986;319:555-559.
18. Ensoli B, Barillari G, Zaki Salahuddin S, Gallo RC, and Wong-Staal F: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (London) 1990;345:84-86.
19. Vogel J, Hinrichs SH, Reynolds SK, Luciw PA, and Jay G: The HIV-1 tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature (London) 1986;335:606-611.
20. Buonaguro L, Barillare G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, and Ensoli B: Effects of the human immunodeficiency virus type-1 Tat protein on the expression of inflammatory cytokines. J Virol 1992;66:7159-7167.
21. Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano V, Baldassarre F, Dragonetti E, Quinto I, and Venuta S: The expression of the interleukin-6 gene is induced by the human immunodeficiency virus 1 Tat protein. J Exp Med 1994;179:961-971.
22. Sastry KJ, Reddy HR, Pandita R, Tolpal K, and Aggarwal BB: HIV-1 Tat gene induces tumor necrosis factor-β (lymphotoxin) in a human B-lymphoblastoid cell line. J Biol Chem 1990;265: 20091-20093.
23. Zauli G, Furlini G, Re MC, Milani D, Capitani S, and La Placa M: Human immunodeficiency virus type 1 (HIV-1) Tat protein stimulates the production of interleukin-6 (IL-6) by peripheral blood monocytes. Microbiologica 1993;16:115-120.
24. Taylor JP, Cupp C, Deaz A, Chowdhury M, Khallili K, Jimenez SA, and Amini S: Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells. Proc Natl Acad Sci USA 1992;89:9617-9621.
25. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, and Gallo RC: Release, uptake and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67:277-287.
26. Frankel AD and Pabo CO: Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988;55:1189-1193.
27. Rodman TC, Pruslin FH, To SE, and Winston R: Human immunodeficiency virus type-1 Tat reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera: Identification of the epitope. J Exp Med 1992;175:1247-1253.
28. Fribach E, Treves A, and Rachmilewitz EA: Spontaneous commitment of murine erythroleukemic cells to terminal differentiation. Cancer Res 1983;43:4136-4142.
29. Gorman CM, Moffat LF, and Howard BH: Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 1982;2:1044-1051.
30. Rando RF, Pellet PE, Luciw PA, Bohan CA, and Srinivasan A: Transactivation of human immunodeficiency virus, by herpes virus. Oncogene 1987;1:13-18.
31. Gorman CM, Merlino GT, Willingham MC, Paslan I, and Howard BH: The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA mediated transfection. Proc Natl Acad Sci USA 1982;79: 6777-6781.
32. Geoffrey J, Maio G, and Maio JJ: RNA transcripts of the human immunodeficiency virus transacting response element can inhibit action of the viral transactivator. Proc Natl Acad Sci USA 1990;87:5817-5821.
33. Lisziewiez J, Sun D, Smythe J, Lusso P, Lori F, Louie A, Markham P, Rossi J, Reitz M, and Gallo RC: Inhibition of human immunodeficiency virus type-1 replication by regulated expression of a polymeric trans acting response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 1993;90:8000-8004.
34. Maniatis T, Fritsch ET, and Sambrook J: Molecular Cloning: A Laboratory Manual. Cold Spring Laboratory Press, Cold Spring Harbor, New York, 1982, pp. 250-251.
35. Nordeen SK, Green PP III, and Fowlkes D: A rapid, sensitive and inexpensive assay for chloramphenicol acetyl transferase. DNA 1987;6:173-178.
36. McGary E, Scanduno AB, Rondon IJ, Wilson RB, and Beckman BS: The effect of erythiopoietin RNA binding protein on erythropoietin mRNA stability. Blood 1995;86:312a. [Abstract 1236]
37. Efremov DG, Dimovski AJ, and Huisman TH: The -158 (C → T) promoter mutation is responsible for the increased transcription of the 3′ γ gene in the Atlanta type of hereditary persistance of fetal hemoglobin. Blood 1994;83:3350-3355.
38. Rhim H, Echetebu CO, Herrmann CH, and Rice AP: Wild type and mutant HIV-1 and HIV-2 Tat protein expressed in Escherichia coli as fusions with glutathione 5-transferase. J AIDS 1994; 7:1116-1121.
39. Donahue RE, Johnson MM, Zon Li, Clark SC, and Groopman JE: Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature (London) 1987;326:200-203.
40. Anderson LC, Jokinen M, and Gahmberg CG: Induction of erythroid differentiation in the human leukemia cell line K562. Nature (London) 1979;278:364-365.
41. Cloe L, McNab A, Hubbell HR, Meo P, Curtis P, and Rovera G: Differential expression of the globin genes in K562 cells induced to differentiate by hemin or butyric acid. Cancer Res 1981; 41:237-243.
42. Weidner DA and Sommadossi J: AZT inhibits globin gene transcription in butyric acid-induced K562 human leukemia cells. Mol Pharmacol 1990;38:797-804.
43. Villeval J, Pellicci PG, Tabilio A, Titeux M, Henri A, Houesche F, Thomopoulos P, Vainchenker W, Garbaz M, Rochant H, Breton-Gorius J, Edwards PA, and Testa U: Erythroid properties of K562 cells: Effect of hemin, butyrate and TPA induction. Exp Cell Res 1983;146:428-435.
44. Koken SE, Greijer AE, Verhoef K, Van Wamel J, and Burkrinskaya AG: Intracellular analysis of in vitro modified HIV Tat protein. J Biol Chem 1994;269:8366-8375.
45. Zauli G, Laplaca M, Vignoli M, Re MC, Gibellini D, Furlini G, Milani D, Marchisio M, Mazzoni M, and Capitani S: An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently tat-transfected cells and required for optimal HIV-1 LTR transactivating activity. J AIDS 1995;10:306-316.
46. Johnston MI and Hoth DF: Present status and future prospects for HIV therapies. Science 1993;260:1286-1293. [Review]
47. Zauli G, Vitale M, Re MC, Furlini G, Zamai L, Falcieri E, Gibellini D, Visani G, Davis BR, Capitani S, and La Placa M: In vitro exposure of HIV-1 induces apoptotic cell death of the factor-dependent TF-1 hematopoietic cell line. Blood 1994;83:167-175.